Background/aims: Many potentially toxic molecules accumulate in the blood during hepatic dysfunction. In clinical practice, it is very difficult to remove bilirubin, the most widely studied toxin, and particularly the unconjugated form, strongly albumin-bound. The aim of this in vitro study was to assess irreversible bilirubin adsorption as a protein-bound compound marker, using Cytosorb® (Cytosorbents Corp.), a new hemoadsorption device designed to remove cytokines.
Methods: We performed 4 in vitro experiments, dynamic and static, with different albumin-bilirubin solutions.
Results: All experiments showed the resin's ability to break the albumin-bilirubin complex (Experiment 1, 2), leading to efficient bilirubin removal for 24 h (Removal Rate: 90% Experiment 3) with minimal albumin loss. No sign of bilirubin release from the charged resin was detected (Experiment 4).
Conclusion: Cytosorb® seems a promising artificial liver support, thanks to its ability to adsorb bilirubin and its proven ability to modulate the cytokines involved in hepatic dysfunction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000492378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic hypothermia in preterm infants under 36 weeks: Case series on outcomes and brain MRI findings.
Eur J Pediatr
January 2025
Neonatology Department. Hospital Sant Joan de Déu, Center for Maternal Fetal and Neonatal Medicine. Neonatal Brain Group, Universitat de Barcelona. Hospital Clínic, Universitat de Barcelona. BCNatal - Barcelona, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Purpose: Perinatal hypoxic-ischemic encephalopathy (HIE) is a significant cause of neonatal brain injury. Therapeutic hypothermia (TH) is the standard treatment for term neonates, but its safety and efficacy in neonates < 36 weeks gestational age (GA) remains unclear. This case series aimed to evaluate the outcomes of preterm infants with HIE treated with TH.
View Article and Find Full Text PDFACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis.
Am J Gastroenterol
January 2025
Kennth C. Griffin Esophageal Center, Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esophagus. It is diagnosed in the setting of symptoms of esophageal dysfunction and an eosinophilic predominant infiltrate in the esophagus. The condition is rapidly increasing in incidence and prevalence and is commonly encountered in gastroenterology and allergy practices, emergency departments, and primary care settings.
View Article and Find Full Text PDFThe frequency and clinical features of posttransplant pneumonia in solid-organ transplantation recipients: A transplant center experience.
Tuberk Toraks
December 2024
Department of Medical Microbiology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Introduction: In solid-organ transplant (SOT) recipients, while survival rates have improved with immunosuppressive therapies, the risk of opportunistic infections has also increased. This study aimed to evaluate the frequency of pneumonia, identify microbiological factors, investigate diagnostic methods, and analyse prognosis.
Materials And Methods: A retrospective study was conducted to identify adult SOT recipients referred to the pulmonary diseases department with a preliminary pneumonia diagnosis between 2011 and 2019.
Leveraging the dual role of ROS in liver diseases with nanomaterials: clearing and amplifying for therapy.
Nanoscale
January 2025
Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
The dual role of reactive oxygen species (ROS) in various liver diseases leads to the potential of nanomaterials in addressing challenges related to liver conditions. Considering the pivotal role of ROS in liver disease progression, the design and application of nanomaterials need to align with distinct disease characteristics and the unique liver microenvironment. By reviewing the interaction between nanomaterials and ROS in liver diseases and their potential applications in liver disease treatment, this work discusses the multifaceted properties of nanomaterials and their high specificity and prospects in liver disease treatments.
View Article and Find Full Text PDFAspiration thrombectomy of the hepatic veins in Budd Chiari Syndrome.
Acta Gastroenterol Belg
January 2025
Department of Radiology, Antwerp University Hospital, Antwerp, Belgium.
Budd-Chiari syndrome (BCS) is a rare, potentially lifethreatening condition characterised by obstruction of the hepatic venous outflow tract due to thrombosis. Treatment typically involves lifelong anticoagulation and relieving the obstruction. This case report introduces hepatic venous thromboaspiration as an additional endovascular technique to achieve recanalisation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!